Skip to content
New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Read More
Investors
Join Our Team
Toggle Main Menu
Immune Medicine
About
Immune Medicine Platform
The Adaptive Immune System
TCR Antigen Map
Publications
Pharma Services
Research & Development Applications
Adaptive Immunosequencing
Drug Discovery
TCR Therapeutics
Antibody Therapeutics
Target Discovery
Pipeline
MRD
About
Clinical Portfolio & Pipeline
Publications
Clinical Diagnostics
clonoSEQ
News & Events
Blog
Pride Month at Adaptive: Celebrating Progress and Community
Decoding Public T-cell Signatures of Disease with Tens of Thousands of T-cell Receptor Repertoires
When the Doctor Becomes the Caregiver
See all posts
Media
Press Releases
Media Resources
Events
Conferences & Events
Our Science
Publications
Research Publications
Credentials
Licenses and Accreditation
Medical
Medical Affairs
Medical Information
Data & Congresses
About Us
About Us
Who We Are
Our Story
Innovation Timeline
Leadership
Corporate Social Responsibility
Careers
Career Listings
Connect
Contact
Investors
Investor Relations
Newsroom
Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004
